Supriya Lifescience Publishes Audited Financial Results for FY26 in Newspapers
Supriya Lifescience Limited announced its audited financial results for the quarter and year ended March 31, 2026. Key figures for the quarter include Total Income of ₹11,008 crore and Profit After Tax of ₹1,621 crore. For the full year, Total Income was ₹56,750 crore and Profit After Tax was ₹6,892 crore. The results were published in Financial Express and Loksatta on May 28, 2026.
This is a routine disclosure of financial results and newspaper publication as per SEBI regulations. It does not introduce new material information that would significantly impact the company's stock or operations.
The announcement is a routine publication of financial results and newspaper advertisement, which is a standard compliance procedure. It does not contain any specific positive or negative news impacting the company's outlook.
Supriya Lifescience Limited has announced the publication of its audited financial results for the quarter and year ended March 31, 2026. The results were published in the Financial Express and Loksatta newspapers on Thursday, May 28, 2026, in compliance with Regulation 47 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company's audited financial results for the quarter ended March 31, 2026, are available on the websites of the BSE Limited (www.bseindia.com) and the National Stock Exchange of India (www.nseindia.com). Additionally, extracts of the audited financial results for the quarter and year ended March 31, 2026, are available on the company's website.
Key financial highlights for the quarter ended March 31, 2026, include Total Income of ₹11,008 crore, Profit Before Tax of ₹2,064 crore, and Profit After Tax of ₹1,621 crore. For the year ended March 31, 2026, Total Income stood at ₹56,750 crore, Profit Before Tax at ₹8,549 crore, and Profit After Tax at ₹6,892 crore. The Earnings Per Share (EPS) for the quarter was ₹36.07, and for the year, it was ₹153.35.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.